BioSpace News Archive

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics.

Sermonix Pharmaceuticals Inc. today announced it is now an industry member of the Metastatic Breast Cancer Alliance, a collective of cancer nonprofits, pharmaceutical and biotech industry members and individual patient advocates working collaboratively to transform and improve the lives of people living with mBC.

Kintara Therapeutics, Inc. today announced the initiation of a REM-001 15-patient clinical trial (NCT05374915) in cutaneous metastatic breast cancer (CMBC) patients.

DEXIS™ announces a new advancement in implant dentistry workflows with the DEXIS digital ecosystem: an interconnected, AI-powered platform for digital implants - combining cutting-edge CBCT, intraoral scanning, diagnostics, and treatment planning.

Nuvig Therapeutics, Inc. today announced the first-in-human dosing of NVG-2089, a proprietary product being developed to treat patients with inflammatory myopathies and severe dermatologic autoimmune disease.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), today announced that it has entered into (i) a marketing and distribution services agreement (the “OTB Agreement”) with an arm’s length marketing firm, Outside The Box Capital Inc.

Trawsfynydd Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering antiviral treatments for respiratory viral diseases, today announced of a first-in-man clinical trial of the novel best-in-class COVID-19 treatment, TRX01, an inhibitor targeting the SARS-CoV-2 viral main protease (3CL, Mpro).

BioVaxys Technology Corp. announced that it has executed the definitive Asset Purchase Agreement dated February 11th, 2024 to acquire the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA.

Freeline Therapeutics Holdings plc and Syncona Ltd announced that Freeline’s shareholders have approved the proposal for Bidco 1354 Limited, a wholly owned subsidiary of Syncona Portfolio Limited, to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share in cash.

The Society of Neurolnterventional Surgery (SNIS) is acknowledging middle meningeal artery embolization (MMAE) as a beneficial adjunctive treatment for chronic subdural hematoma in light of new research.